X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indoco Remedies Fact Sheet, Indoco Remedies Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indoco Remedies Fact Sheet   (INDOCO)

Here is the latest financial fact sheet of Indoco Remedies. For more details, see the Indoco Remedies quarterly results and Indoco Remedies share price and chart. For a sector overview, read our pharmaceuticals sector report.

INDOCO REMEDIES Price History

Price Rs 192.7
Mkt Cap Rs m 17,762
Vol '000 4.0
P/E X 22.9
P/CF X 12.4
EPS (TTM) Rs 8.4
% ch % 3.6
No. of shares m 92.18
% ch week % 3.2
% ch 1-mth % 0.7
% ch 12-mth % -29.2
52 week H/L Rs 360.4/179.0
(As on Jun 29, 2017 03:36:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

INDOCO REMEDIES Financials

No. of Mths
Year Ending
12
Mar-12
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
INDOCO REMEDIES EQUITY SHARE DATA
High Rs48583162378412 
Low Rs3605155131263 
Sales per share (Unadj.) Rs462.868.579.593.0108.9 
Earnings per share (Unadj.) Rs37.74.66.39.09.0 
Diluted earnings per shareRs5.04.66.39.09.0 
Cash flow per share (Unadj.) Rs53.47.29.614.115.6 
Dividends per share (Unadj.) Rs1.101.101.401.601.60 
Adj. dividends per shareRs0.151.101.401.601.60 
Dividend yield (eoy) %0.31.61.30.60.5 
Book value per share (Unadj.) Rs309.244.949.656.363.4 
Adj. book value per shareRs41.244.949.656.363.4 
Shares outstanding (eoy) m12.2992.1592.1592.1592.15 
Bonus/Rights/Conversions  -FV2, B1:2--- 
Price / Sales ratio x0.91.01.42.73.1 
Avg P/E ratio x11.214.517.228.337.5 
P/CF ratio (eoy) x7.99.311.218.021.7 
Price / Book Value ratio x1.41.52.24.55.3 
Dividend payout %2.923.722.217.817.8 
Avg Mkt Cap Rs m5,1936,1749,98923,43831,087 
No. of employees `000NANANANA5.7 
Total wages/salary Rs m8191,0791,2951,4001,826 
Avg. sales/employee Rs ThNMNMNMNM1,754.8 
Avg. wages/employee Rs ThNMNMNMNM319.3 
Avg. net profit/employee Rs ThNMNMNMNM145.1 
INDOCO REMEDIES INCOME DATA
Net Sales Rs m5,6886,3087,3268,57010,038 
Other income Rs m2315181711 
Total revenues Rs m5,7106,3237,3448,58710,049 
Gross profit Rs m8469261,2041,6551,723 
Depreciation Rs m193237309471604 
Interest Rs m163219189106125 
Profit before tax Rs m5134867231,0961,006 
Minority Interest Rs m00-100 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m4958143267176 
Profit after tax Rs m464427580828830 
Gross profit margin %14.914.716.419.317.2 
Effective tax rate %9.611.919.824.417.5 
Net profit margin %8.16.87.99.78.3 
INDOCO REMEDIES BALANCE SHEET DATA
Current assets Rs m2,6202,7553,0463,8544,632 
Current liabilities Rs m1,8231,9932,0222,6212,887 
Net working cap to sales %14.012.114.014.417.4 
Current ratio x1.41.41.51.51.6 
Inventory Days Days6554556460 
Debtors Days Days7374696669 
Net fixed assets Rs m3,3423,5923,6944,0224,296 
Share capital Rs m123184184184184 
"Free" reserves Rs m3,6703,9504,3804,9955,650 
Net worth Rs m3,8004,1424,5725,1885,843 
Long term debt Rs m462274138129397 
Total assets Rs m6,5166,9197,2948,4569,638 
Interest coverage x4.13.24.811.49.0 
Debt to equity ratio x0.10.1000.1 
Sales to assets ratio x0.90.91.01.01.0 
Return on assets %9.69.310.511.09.9 
Return on equity %12.210.312.716.014.2 
Return on capital %15.915.919.422.618.1 
Exports to sales %34.533.533.936.240.3 
Imports to sales %6.85.45.47.57.7 
Exports (fob) Rs m1,9602,1162,4803,1014,044 
Imports (cif) Rs m389343396643773 
Fx inflow Rs m1,9602,1162,4803,1014,044 
Fx outflow Rs m4754455498191,017 
Net fx Rs m1,4851,6711,9312,2823,027 
INDOCO REMEDIES CASH FLOW
From Operations Rs m 691 687 988 1,090 1,133 
From Investments Rs m -639 -426 -410 -884 -1,120 
From Financial Activity Rs m -174 -244 -590 -199 -15 
Net Cashflow Rs m -122 17 -12 7 -1 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 59.2%
Foreign collaborators 0.0%
Indian inst/Mut Fund 12.5%
FIIs 6.0%
ADR/GDR 0.0%
Free float 22.4%
Shareholders 12,805
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF 166, Indoco House, CST Road, kalina, Santacruz (E), Mumbai - 400 098
E-MAIL sunil.joshi@indoco.com WEB www.indoco.com
TELEPHONE (022) 2654 1851 FAX (022) 2652 3067
SECTOR MISCELLANEOUS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR Patkar & Pendse
CHM: Suresh G. Kare (MD) COMP SEC: Sunil D. Joshi YEAR OF INC: 1945 BSE CODE: 532612 FV (Rs): 2 DIV YIELD (%): 0.8

More Miscellaneous Company Fact Sheets:   PIRAMAL ENTERPRISES  NOVARTIS  FULFORD INDIA  STRIDES SHASUN LTD  MERCK LTD  

Compare INDOCO REMEDIES With:   PIRAMAL ENTERPRISES  NOVARTIS  FULFORD INDIA  STRIDES SHASUN LTD  MERCK LTD  

Compare INDOCO REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trims Early Gains to Finish Flat; Indigo Slips 2.3%(Closing)

Indian share markets trimmed its early gains in the afternoon session to finish just above the dotted line amid mixed global cues.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

The 'Multibagger IPOs' You Should Be Betting On(The 5 Minute Wrapup)

Jun 22, 2017

Multibagger IPOs are few and far between. Here's how to spot them...

After Farm Loans, Will Govts Waive Off Mudra Loans Next?(Vivek Kaul's Diary)

Jun 19, 2017

If borrowers organise themselves and ask the government to waive off their loans, the government will find it very difficult to say no, having already established a precedent.

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Walter Schloss' Investing Record(Chart Of The Day)

Jun 17, 2017

In a market full of one-hit-wonders, this investor obviously had a formula that worked. And through the think-and-thin of the market.

11 Hidden Costs Associated With Your Home Loan(Outside View)

Jun 16, 2017

Various costs associated with a home loan.

More

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - THOMAS COOK INDIA COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS